LBA62 Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study

A.R.R. Filippi,M.R. García-Campelo,J-B. Paoli, D. Kowalski, C. Bennati, P. Borghetti,D.L. Cortinovis,A. Delmonte, C. Genova, S. Van Hulst, R. Mroz,S. Nawrocki, I. Toledano, G. Tonini,I. Diaz Perez, N.E. Georgoulia, K. Foroutanpour,R. Dziadziuszko

Annals of Oncology(2023)

引用 0|浏览1
暂无评分
关键词
radiotherapy,chemotherapy,unresectable stage iii nsclc
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要